Presbyopia Epidemiology Summary
- Presbyopia can be classified including incipient presbyopia, functional presbyopia, absolute presbyopia, premature presbyopia, and nocturnal presbyopia.
- Age is the major risk factor for the development of presbyopia, although the condition may occur prematurely as the result of factors such as trauma, systemic disease, cardiovascular disease, or a drug side effect.
- Based on DelveInsight's assessment in 2025, the 7MM had ~250,000 thousands diagnosed prevalent cases of presbyopia.
- In the US, the age-specific diagnosed prevalent cases of presbyopia in 2025 were highest (~35) in the age group 60–69 years, followed by less than 60 years (~25) and the lowest in the age group more than 80 years.
Presbyopia Epidemiology Forecast in the 7MM
- 2025 Diagnosed Prevalence of Presbyopia: ~298,600 thousands
- 2036 Diagnosed Prevalence of Presbyopia: ~XX
- Presbyopia Growth Rate (2026–2036): ~1% CAGR
DelveInsight's ‘Presbyopia – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the presbyopia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
- North America : The US;
- Europe: Germany, France, Italy, and Spain and the UK;
- Asia-Pacific: Japan;
|
|
Presbyopia Epidemiology CAGR
(Forecast period)
|
~1% (2026–2036)
|
|
Presbyopia Epidemiology Segmentation Analysis
|
Patient Burden Assessment
- Presbyopia Total Prevalent Cases
- Presbyopia Total Diagnosed Prevalent Cases
- Presbyopia Age-specific Diagnosed Prevalent Cases
- Presbyopia Severity-specific Diagnosed Prevalent Cases
- Presbyopia Gender-specific Diagnosed Prevalent Cases
- Presbyopia Total Treated Cases
|
Presbyopia Understanding and Diagnosis Algorithm
Presbyopia Overview
Presbyopia is a common, age-related refractive condition characterized by the progressive loss of the eye’s ability to focus on near objects due to reduced accommodative function. It occurs primarily because of age-related changes in the crystalline lens, including reduced elasticity, increased lens rigidity, and decreased ability of the ciliary muscle–lens system to change shape during near vision tasks. Presbyopia typically develops after the age of 40 and affects nearly all individuals by 50–60 years of age, regardless of gender or baseline refractive status. Common symptoms include difficulty reading small print, eye strain, headaches during near tasks, and the need to hold reading material farther away. With increasing screen use and an aging global population, presbyopia represents a significant and growing ophthalmic burden worldwide.
Further details are provided in the report.
Presbyopia Diagnosis
Diagnosis of presbyopia is primarily based on clinical evaluation, patient symptoms, and comprehensive ophthalmic examination. A routine eye examination includes assessment of near and distance visual acuity, refraction testing, and evaluation of the patient’s ability to focus on near objects. The amplitude of accommodation and near point of accommodation may be measured to assess accommodative decline. Additional examinations, including slit-lamp evaluation and retinal assessment, may be performed to rule out other age-related ocular conditions such as cataracts, macular degeneration, or other causes of reduced near vision. Presbyopia is generally diagnosed when patients demonstrate reduced near visual acuity despite appropriate correction of distance vision.
Further details are provided in the report.
Presbyopia Epidemiology
Key Findings from Presbyopia Epidemiological Analysis and Forecast
- In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of pesbyopia, with nearly 108,000 thousands cases in 2025.
- Among the EU4 nad the UK, Germany had the highest (~25%) cases of prevalent cases of presbyopia followed by Italy, and Spain had the lowest number of cases in 2025.
- Gender-specific cases of presbyopia were highest in females (~55%) than in males in US in 2025.
- Among the EU4 and the UK, severity specifc cases were more in moderate to severe (~75%) than in mild in 2025.
Scope of the Report
- The report covers a segment of a descriptive overview of presbyopia, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Presbyopia Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of presbyopia? What will be the growth opportunities across the 7MM concerning the patient population with presbyopia?
- What is the historical and forecasted presbyopia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1 Key Insights
2 Report Introduction
3 Executive Summary of Presbyopia
4 Epidemiology Methodology of Presbyopia
5 Presbyopia Market Overview at a Glance
5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM
6 Disease Background And Overview of Presbyopia
6.1 Introduction
6.2 Signs and Symptoms
6.3 Pathophysiology
6.4 Etiology
6.5 Diagnosis
6.6 Diagnostic Guidelines
7 Epidemiology and Patient Population of Presbyopia
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Presbyopia Total Prevalent Cases in the 7MM
7.4 The United States
7.4.1 Presbyopia Total Prevalent Cases in the United States
7.4.2 Presbyopia Total Diagnosed Prevalent Cases in the United States
7.4.3 Presbyopia Age-specific Diagnosed Prevalent Cases in the United States
7.4.4 Presbyopia Severity-specific Diagnosed Prevalent Cases in the United States
7.4.5 Presbyopia Gender-specific Diagnosed Prevalent Cases in the United States
7.4.6 Presbyopia Total Treated Cases in the United States
7.5 EU4 and the UK
7.5.1 Presbyopia Total Prevalent Cases in the EU4 and the UK
7.5.2 Presbyopia Total Diagnosed Prevalent Cases in the EU4 and the UK
7.5.3 Presbyopia Age-specific Diagnosed Prevalent Cases in the EU4 and the UK
7.5.4 Presbyopia Severity-specific Diagnosed Prevalent Cases in the EU4 and the UK
7.5.5 Presbyopia Gender-specific Diagnosed Prevalent Cases in the EU4 and the UK
7.5.6 Presbyopia Total Treated Cases in the EU4 and the UK
7.6 Japan
7.6.1 Presbyopia Total Prevalent Cases in Japan
7.6.2 Presbyopia Total Diagnosed Prevalent Cases in Japan
7.6.3 Presbyopia Age-specific Diagnosed Prevalent Cases in Japan
7.6.4 Presbyopia Severity-specific Diagnosed Prevalent Cases in Japan
7.6.5 Presbyopia Gender-specific Diagnosed Prevalent Cases in Japan
7.6.6 Presbyopia Total Treated Cases in Japan
8 Patient Journey of Presbyopia
9 KOL Views of Presbyopia
10 Appendix
10.1 Bibliography
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
List of Tables:
List of Table
Table 1: Summary of Presbyopia Epidemiology (2022–2036)
Table 2: Comparison of the guidelines
Table 3: Total Prevalent Cases of Presbyopia in the 7MM (2022-2036)
Table 4: Presbyopia Total Prevalent Cases in the United States (2022-2036)
Table 5: Presbyopia Total Diagnosed Prevalent Cases in the United States (2022-2036)
Table 6: Presbyopia Age-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Table 7: Presbyopia Severity-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Table 8: Presbyopia Gender-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Table 9: Presbyopia Total Treated Cases in the United States (2022-2036)
Table 10: Presbyopia Total Prevalent Cases in Germany (2022-2036)
Table 11: Presbyopia Total Diagnosed Prevalent Cases in Germany (2022-2036)
Table 12: Presbyopia Age-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Table 13: Presbyopia Severity-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Table 14: Presbyopia Gender-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Table 15: Presbyopia Total Treated Cases in Germany (2022-2036)
Table 16: Presbyopia Total Prevalent Cases in France (2022-2036)
Table 17: Presbyopia Total Diagnosed Prevalent Cases in France (2022-2036)
Table 18: Presbyopia Age-specific Diagnosed Prevalent Cases in France (2022-2036)
Table 19: Presbyopia Severity-specific Diagnosed Prevalent Cases in France (2022-2036)
Table 20: Presbyopia Gender-specific Diagnosed Prevalent Cases in France (2022-2036)
Table 21: Presbyopia Total Treated Cases in France (2022-2036)
Table 22: Presbyopia Total Prevalent Cases in Italy (2022-2036)
Table 23: Presbyopia Total Diagnosed Prevalent Cases in Italy (2022-2036)
Table 24: Presbyopia Age-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Table 25: Presbyopia Severity-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Table 26: Presbyopia Gender-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Table 27: Presbyopia Total Treated Cases in Italy (2022-2036)
Table 28: Presbyopia Total Prevalent Cases in Spain (2022-2036)
Table 29: Presbyopia Total Diagnosed Prevalent Cases in Spain (2022-2036)
Table 30: Presbyopia Age-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Table 31: Presbyopia Severity-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Table 32: Presbyopia Gender-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Table 33: Presbyopia Total Treated Cases in Spain (2022-2036)
Table 34: Presbyopia Total Prevalent Cases in the United Kingdom (2022-2036)
Table 35: Presbyopia Total Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Table 36: Presbyopia Age-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Table 37: Presbyopia Severity-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Table 38: Presbyopia Gender-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Table 39: Presbyopia Total Treated Cases in the United Kingdom (2022-2036)
Table 40: Presbyopia Total Prevalent Cases in Japan (2022-2036)
Table 41: Presbyopia Total Diagnosed Prevalent Cases in Japan (2022-2036)
Table 42: Presbyopia Age-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Table 43: Presbyopia Severity-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Table 44: Presbyopia Gender-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Table 45: Presbyopia Total Treated Cases in Japan (2022-2036)
List of Figures:
List of Figures
Figure 1: Presbyopia: Age-Related Loss of Near Vision Focus
Figure 2: Summary of the impact of uncorrected presbyopia on daily activities
Figure 3: Flow chart depicting the visual acuity measurements required to categorise individuals as having no need, met need, undermet need and unmet need in the context of calculating effective coverage of refractive error (for near vision)
Figure 4: Total Prevalent Cases of Presbyopia in the 7MM (2022-2036)
Figure 5: Presbyopia Total Prevalent Cases in the United States (2022-2036)
Figure 6: Presbyopia Total Diagnosed Prevalent Cases in the United States (2022-2036)
Figure 7: Presbyopia Age-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Figure 8: Presbyopia Severity-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Figure 9: Presbyopia Gender-specific Diagnosed Prevalent Cases in the United States (2022-2036)
Figure 10: Presbyopia Total Treated Cases in the United States (2022-2036)
Figure 11: Presbyopia Total Prevalent Cases in Germany (2022-2036)
Figure 12: Presbyopia Total Diagnosed Prevalent Cases in Germany (2022-2036)
Figure 13: Presbyopia Age-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Figure 14: Presbyopia Severity-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Figure 15: Presbyopia Gender-specific Diagnosed Prevalent Cases in Germany (2022-2036)
Figure 16: Presbyopia Total Treated Cases in Germany (2022-2036)
Figure 17: Presbyopia Total Prevalent Cases in France (2022-2036)
Figure 18: Presbyopia Total Diagnosed Prevalent Cases in France (2022-2036)
Figure 19: Presbyopia Age-specific Diagnosed Prevalent Cases in France (2022-2036)
Figure 20: Presbyopia Severity-specific Diagnosed Prevalent Cases in France (2022-2036)
Figure 21: Presbyopia Gender-specific Diagnosed Prevalent Cases in France (2022-2036)
Figure 22: Presbyopia Total Treated Cases in France (2022-2036)
Figure 23: Presbyopia Total Prevalent Cases in Italy (2022-2036)
Figure 24: Presbyopia Total Diagnosed Prevalent Cases in Italy (2022-2036)
Figure 25: Presbyopia Age-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Figure 26: Presbyopia Severity-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Figure 27: Presbyopia Gender-specific Diagnosed Prevalent Cases in Italy (2022-2036)
Figure 28: Presbyopia Total Treated Cases in Italy (2022-2036)
Figure 29: Presbyopia Total Prevalent Cases in Spain (2022-2036)
Figure 30: Presbyopia Total Diagnosed Prevalent Cases in Spain (2022-2036)
Figure 31: Presbyopia Age-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Figure 32: Presbyopia Severity-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Figure 33: Presbyopia Gender-specific Diagnosed Prevalent Cases in Spain (2022-2036)
Figure 34: Presbyopia Total Treated Cases in Spain (2022-2036)
Figure 35: Presbyopia Total Prevalent Cases in the United Kingdom (2022-2036)
Figure 36: Presbyopia Total Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Figure 37: Presbyopia Age-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Figure 38: Presbyopia Severity-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Figure 39: Presbyopia Gender-specific Diagnosed Prevalent Cases in the United Kingdom (2022-2036)
Figure 40: Presbyopia Total Treated Cases in the United Kingdom (2022-2036)
Figure 41: Presbyopia Total Prevalent Cases in Japan (2022-2036)
Figure 42: Presbyopia Total Diagnosed Prevalent Cases in Japan (2022-2036)
Figure 43: Presbyopia Age-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Figure 44: Presbyopia Severity-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Figure 45: Presbyopia Gender-specific Diagnosed Prevalent Cases in Japan (2022-2036)
Figure 46: Presbyopia Total Treated Cases in Japan (2022-2036)
